All In Biotech

Drug Trial Radar · NCT07616206

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems

Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
vTv TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.

Conditions

  • Type 1 Diabetes (T1D)

Interventions

  • Cadisegliatin 800 mg QDDrug

    Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin

  • PlaceboDrug

    Placebo (insulin alone)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the change in Time in Range (TIR)Time frame: last 2 weeks of the two 6-week treatment periods

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Paradigm Clinical Research -Modesto

    Modesto, California · Recruiting

  • Paradigm Clinical Research Centers, LLC

    San Diego, California · Recruiting

  • Barbara Davis Center for Diabetes

    Aurora, Colorado · Recruiting

  • Atlanta Diabetes Associates

    Atlanta, Georgia · Recruiting

  • UNC Eastowne Medical Office Building

    Chapel Hill, North Carolina · Recruiting

  • Texas Diabetes & Endocrinology, P.A.

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.